KCT0008817
Not yet recruiting
未知
ecessity of post-mastectomy radiotherapy in breast cancer patients with an excellent response after neoadjuvant chemotherapy: A phase 3, multicenter, randomized controlled study (NEMESIS)
Yonsei University Health System, Gangnam Severance Hospital0 sites1,314 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Enrollment
- 1314
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients 20 years of age or older with histologically confirmed invasive breast cancer.
- •2\) Patients with clinical stage IIB\-III at the time of diagnosis (including cases of cT1N1 with multiple masses observed during clinical stage IIA). Patients are considered node positive if they have either suspected lymph node metastasis on imaging studies (U/S, breast MRI, PET\-CT) or confirmed by pathology.
- •3\) Patients who have undergone mastectomy after prior neoadjuvant chemotherapy.
- •4\) Patients with pathologic complete response (pCR) or residual cancer burden (RCB) class 0\-I based on postoperative pathology.
- •Complete remission is defined as ypT0/is ypN0\.
- •RCB class 0 means complete remission and RCB class 1 is defined as an RCB score \=0\-1\.36 as determined by the pathology department at the site.
- •5\) Patients not previously treated for invasive breast cancer.
- •6\) Patients with a systemic performance status of 0\-2 based on ECOG.
- •7\) Patients who signed the informed consent prior to study entry.
Exclusion Criteria
- •1\) Patients with a prior history of invasive breast cancer (patients with a prior history of intraepithelial carcinoma of the breast may be enrolled)
- •2\) Patients with bilateral breast cancer
- •3\) Patients with a prior diagnosis of cancer other than breast cancer within 5 years (however, adequately treated skin cancer other than melanoma and thyroid cancer are eligible for enrollment.)
- •4\) Patients with pathologically or imaging confirmed systemic metastases
- •5\) Patients with a history of prior irradiation or isotope therapy to the rib cage and axillary region contralateral to the breast cancer lesion
- •6\) Patients with suspected supraclavicular/infraclavicular lymph node metastases and internal mammary lymph node metastases
- •7\) Pregnant or lactating patients
- •8\) Patients who have difficulty understanding the contents of the consent form and completing the survey.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and MastectomyBreast CancerNCT05993559Gangnam Severance Hospital1,314
Recruiting
Not Applicable
The Postoperative Radiotherapy after Breast Conserving Surgery or Mastectomy in N1 Breast Cancer Patients: A Prospective, Multicenter, Phase III Clinical Trial (PORT-N1)NeoplasmsKCT0007504Seoul National University Hospital1,106
Recruiting
Phase 3
Randomized trial evaluating role of post mastectomy radiotherapy in women with node negative early breast cancerHealth Condition 1: null- Women with early breast cancer who have undergone upfront mastectomy for breast cancer and have negative nodesCTRI/2016/12/007532Tata Memorial Centre
Completed
Not Applicable
Post mastectomy radiotherapy among patients with T1-T2 1-3 node positive disease. A retrospective cohort studyRadiotherapy patientsC50Malignant neoplasm of breastDRKS00024402Aga Khan University Hospital755
Terminated
Phase 3
Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive NodesBreast CancerNCT00805597Chinese Academy of Medical Sciences40